196
Participants
Start Date
October 31, 2000
Primary Completion Date
October 31, 2001
Study Completion Date
October 31, 2001
placebo
Once daily injection, under the skin (s.c.) for 12 weeks
liraglutide
Once daily injection, under the skin (s.c.) for 12 weeks
glimepiride
Tablets administered orally according to current treatment guidelines. Dose adjusted according to the glycaemic response
Novo Nordisk Investigational Site, Bekkestua
Novo Nordisk Investigational Site, Copenhagen
Novo Nordisk Investigational Site, Elverum
Novo Nordisk Investigational Site, Hvidovre
Novo Nordisk Investigational Site, Køge
Novo Nordisk Investigational Site, Kolding
Novo Nordisk Investigational Site, Thisted
Novo Nordisk Investigational Site, Århus C
Novo Nordisk Investigational Site, Harstad
Novo Nordisk Investigational Site, Oslo
Novo Nordisk Investigational Site, Gothenburg
Novo Nordisk Investigational Site, Grästorp
Novo Nordisk Investigational Site, Lund
Novo Nordisk Investigational Site, Örebro
Novo Nordisk Investigational Site, Uppsala
Novo Nordisk Investigational Site, Ayrsh
Novo Nordisk Investigational Site, Church Village
Novo Nordisk Investigational Site, Edinburgh
Novo Nordisk Investigational Site, Enfield
Novo Nordisk Investigational Site, Hull
Novo Nordisk Investigational Site, Leicester
Novo Nordisk Investigational Site, Liverpool
Novo Nordisk Investigational Site, Northampton
Novo Nordisk Investigational Site, Nottingham
Novo Nordisk Investigational Site, Oxford
Novo Nordisk Investigational Site, Plymouth
Novo Nordisk Investigational Site, Rugby
Novo Nordisk Investigational Site, Sheffield
Novo Nordisk Investigational Site, Worksop
Lead Sponsor
Novo Nordisk A/S
INDUSTRY